A Phase I Study of GC33 plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma
[Protocol 10-021] |
Abou-Alfa, Ghassan, MD |
A Phase I/II Study of Gemcitabine, Cisplatin, and MEK162 as Initial Treatment for Advanced Bile Duct or Gallbladder Cancer
[Protocol 13-004] |
Lowery, Maeve, MD |
A Phase I/II Study of M402 in Combination with Gemcitabine in Patients with Previously Untreated Metastatic Pancreatic Cancer
[Protocol 12-078] |
O'Reilly, Eileen, MD |
A Phase IB Dose-Escalation and Safety Study of LDE225 plus Gemcitabine in Patients with Locally Advanced or Metastatic Pancreatic Cancer
[Protocol 12-036] |
Yu, Kenneth, MD |
A Phase IB Study of BKM120 plus MEK162 in Select Patients with Advanced Solid Tumors
[Protocol 11-117] |
Gounder, Mrinal, MD |
A Phase IB Study of Vismodegib in Patients with Liver Cancer with Varying Degrees of Kidney and Liver Function
[Protocol 12-031] |
Abou-Alfa, Ghassan, MD |
A Phase II Study of Everolimus, Leuprolide/Letrozole, and Everolimus/Leuprolide/Letrozole in Patients with Inoperable Fibrolamellar Hepatocellular Carcinoma
[Protocol 11-211] |
Abou-Alfa, Ghassan, MD |
A Phase II Study of GC33 in Patients with Advanced Hepatocellular Carcinoma
[Protocol 12-145] |
Abou-Alfa, Ghassan, MD |
A Phase II Study of Hepatic Arterial Infusion with Floxuridine and Dexamethasone plus Systemic Gemcitabine and Oxaliplatin in Patients with Inoperable Intrahepatic Cholangiocarcinoma
[Protocol 13-066] |
Jarnagin, William, MD |
A Phase II Study of Sorafenib in Children and Young Adults with Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, or Papillary Thyroid Cancer
[Protocol 12-139] |
Trippett, Tanya, MD |
A Phase II Study of Sorafenib plus Doxorubicin in Patients with Liver Cancer that Continued Growing with Sorafenib Therapy
[Protocol 12-259] |
Abou-Alfa, Ghassan, MD |
A Phase III Study of ADI-PEG20/Supportive Care or Placebo/Supportive Care in Patients with Advanced Liver Cancer
[Protocol 11-081] |
Abou-Alfa, Ghassan, MD |
A Phase III Study of Sorafenib plus Doxorubicin versus Sorafenib Alone in Patients with Advanced Hepatocellular Cancer
[Protocol 11-039] |
Abou-Alfa, Ghassan, MD |
A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Pancreatic Cancer
[Protocol 10-083] |
Goodman, Karyn, MD |
A Pilot Study to Identify Patient Factors Impacting Adherence to Oral Chemotherapy
[Protocol 11-194] |
Ginex, Pamela, RN, EDD |
A Study of SOM230 to Reduce the Risk of Fistulas, Leaks, and Abscesses After Pancreatic Surgery
[Protocol 09-039] |
Allen, Peter, MD |
Memorial Sloan-Kettering Cancer Center Pancreatic Tumor Registry
[Protocol 02-102] |
Kurtz, Robert, MD |
Treatment of Children with All Stages of Hepatoblastoma
[Protocol 10-046] |
Kobos, Rachel, MD |
Two Phase II Studies of Veliparib for Pancreatic Cancer with a BRCA or PALB2 Mutation: Gemcitabine & Cisplatin with/without Veliparib in Untreated Pancreatic Cancer (Part I) & Veliparib Alone for Patients with Previously Treated Pancreatic Cancer (Part II
[Protocol 12-045] |
O'Reilly, Eileen, MD |
